Core Viewpoint - Myriad Genetics, Inc. has announced preliminary financial results for Q4 and full year 2025, along with financial guidance for 2026, indicating growth expectations in revenue and adjusted EBITDA [1][6]. Financial Results - The company anticipates total revenues for Q4 2025 to be between $207 million and $209 million [7]. - For the full year 2025, total revenues are expected to be between $822 million and $824 million [7]. - The preliminary results are subject to finalization and external audit, meaning they may change before the official earnings call in February 2026 [4]. 2026 Financial Guidance - Myriad Genetics projects 2026 revenue guidance to be between $860 million and $880 million, reflecting an approximate 6% increase compared to the mid-point of the preliminary 2025 revenue range [6]. - The adjusted gross margin for 2026 is expected to be between 68% and 69%, incorporating impacts from new product launches [6]. - Adjusted EBITDA for 2026 is projected to be between $37 million and $49 million, indicating an expected growth of approximately 43% over the mid-point of the previous full year 2025 guidance range [6].

Core Viewpoint - Myriad Genetics, Inc. will hold its third quarter 2025 earnings conference call on November 3, 2025, at 4:30 pm ET, with earnings released after market close on the same day [1]. Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine, focusing on advancing health and well-being through molecular tests that assess disease risk and guide treatment decisions [3]. Conference Call Details - The conference call will provide a financial overview and business update regarding the company's performance for the third quarter of 2025 [1]. - A live webcast of the conference call will be available on Myriad's Investor Relations website, and an archived version will be accessible after the call [2].

Company Overview - Myriad Genetics, Inc. is a leader in molecular diagnostic testing and precision medicine, focusing on advancing health and well-being for all [3] - The company develops molecular tests that assess disease risk and guide treatment decisions, aiming to improve patient care and reduce healthcare costs [3] Upcoming Events - Myriad management will participate in two healthcare conferences: the Wells Fargo Healthcare Conference on September 4 at 3:45 PM ET and the Morgan Stanley Annual Global Healthcare Conference on September 10 at 7:45 AM ET [1][4] - Live and archived webcasts of both presentations will be available at investor.myriad.com [2]

Core Points - Myriad Genetics, Inc. will hold its second quarter 2025 earnings conference call on August 5, 2025, at 4:30 PM ET [1] - The company's quarterly earnings will be released the same day after market close [1] - Management will provide a financial overview and business update during the call [1] Company Overview - Myriad Genetics is a leader in molecular diagnostic testing and precision medicine [3] - The company develops molecular tests that assess disease risk and guide treatment decisions, aiming to improve patient care and reduce healthcare costs [3] Investor Information - A live webcast of the conference call will be available on Myriad's Investor Relations website [2] - Participants can register for the call to receive a dial-in number and unique PIN [2] - An archived version of the webcast will be accessible after the call [2]